Intellia files CRISPR drug after historic phase 3 readout
Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.
Lilly's M&A team strikes again with $2.3bn Ajax takeover
With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.
GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
New NIHR-funded TRC for Parkinson’s disease
The launch of a new national research collaboration focused on Parkinson’s disease has been announced.
Lilly falls on slower start for Foundayo versus Wegovy
Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers